CERo Therapeutics Holdings, Inc. (CERO) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en South San Francisco, CA, United States. El CEO actual es Christopher Ehrlich.
CERO tiene fecha de IPO 2021-11-30, 8 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $38.57K.
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
